An interesting finding in this work is that LDM is relatively more potent in colon cancer cells carrying endogenously high EZH2 expression (Figure 2a), and can selectively deplete EZH2 instead of other histone lysine methyltransferases (Figure 4 and Supplementary Figure S3). This evidence concerns the gene EZH2 and malignant colon neoplasm.